274 related articles for article (PubMed ID: 16783561)
1. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
[TBL] [Abstract][Full Text] [Related]
2. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
[TBL] [Abstract][Full Text] [Related]
3. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
4. Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve.
Niioka T; Uno T; Yasui-Furukori N; Shimizu M; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Oct; 62(10):855-61. PubMed ID: 16915367
[TBL] [Abstract][Full Text] [Related]
5. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Chirality; 2005 Jun; 17(6):338-44. PubMed ID: 15856433
[TBL] [Abstract][Full Text] [Related]
6. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
[TBL] [Abstract][Full Text] [Related]
8. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
[TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
[TBL] [Abstract][Full Text] [Related]
10. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
Yang JC; Yang YF; Uang YS; Lin CJ; Wang TH
Br J Clin Pharmacol; 2009 May; 67(5):503-10. PubMed ID: 19552744
[TBL] [Abstract][Full Text] [Related]
12. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
Hayato S; Hasegawa S; Hojo S; Okawa H; Abe H; Sugisaki N; Munesue M; Horai Y; Ohnishi A
Eur J Clin Pharmacol; 2012 May; 68(5):579-88. PubMed ID: 22108775
[TBL] [Abstract][Full Text] [Related]
13. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
[TBL] [Abstract][Full Text] [Related]
14. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
15. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
16. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
[TBL] [Abstract][Full Text] [Related]
19. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Sugimoto M; Furuta T; Shirai N; Nakamura A; Kajimura M; Hishida A; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2005 Apr; 77(4):302-11. PubMed ID: 15903128
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Lin CJ; Yang JC; Uang YS; Chern HD; Wang TH
Pharmacotherapy; 2003 Jun; 23(6):711-9. PubMed ID: 12820812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
